Member Profile

Immunwork, Inc. was founded in 2014. We focus on the research, development and commercialization of a series of new drugs, which are created based on our proprietary “T-ETM pharmaceuticals” technology platform, for treating multiple types of cancer, diabetes, non-alcoholic steatohepatitis (NASH), obesity, pathological blood clots, osteoporosis, and other selected severe clinical conditions.
The drug-design platform can be employed for constructing antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting peptide drugs, and other pharmaceutical configurations. Five drug candidates have been identified and are planned to enter preclinical development, including TE-8214 and TE-1146 for treating oncology, TE-8104 for treating diabetes, and TE-6168 for treating pathological clots.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2014 Immunwork, Inc. was founded in October 2014.
   2019 After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island.
   2021 T-E Pharma Holding (TEPH) is to issue common shares for raising.
   2021 TE-8105 is recognized by CDE as Index Case